Cambrex is a leading pharma CDMO, offering a full suite of integrated services to many of the preeminent pharmaceutical companies globally. The Company provides drug substance, drug product and early stage testing & development services across the entire drug lifecycle from pre-clinical to commercial stages, with a focus on branded (“innovator”) drugs.



Why we backed them

  • To capitalize on the large and attractive pharma CDMO market (c.$60bn) that exhibits strong and resilient growth supported by attractive demographics, robust R&D pipelines and continued outsourcing
  • To back the market leader in small molecule CDMO with an industry-leading customer reputation and an excellent quality and regulatory track record
  • To unlock the potential of a scarce CDMO platform with an integrated service offering spanning the entire drug development life-cycle

The investment strategy

  • To support ongoing growth of Cambrex’s integrated services offering and cross-selling efforts to customers
  • To broaden the company’s services by adding new capabilities across all three business units
  • To pursue M&A to expand Cambrex’s geographic footprint and increase scale
  • To achieve operational and capital efficiencies across the business

The metrics


Facilities across North America and Europe